Drugs Made In America Acquisition (DMIIR) Income from Continuing Operations (2025)

Drugs Made In America Acquisition's (DMIIR) quarterly Income from Continuing Operations came in at 4588973.0 in Q4 2025, up 10041.88% on a QoQ basis from 46158.0 in Q3 2025.

Drugs Made In America Acquisition (DMIIR) Income from Continuing Operations (2025) Analysis & Trends

Drugs Made In America Acquisition (DMIIR) has 1 years of Income from Continuing Operations data on file, last reported at 4588973.0 in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 EQV Ventures Acquisition 480.75 Mn 480.75 Mn - 3.75 Mn
2 Agriculture & Natural Solutions Acquisition 393.29 Mn 393.29 Mn - -612,993.00
3 Berto Acquisition 314.56 Mn 314.35 Mn - 2.22 Mn
4 GP-Act III Acquisition 313.66 Mn 313.66 Mn - 2.89 Mn
5 Centurion Acquisition 311.65 Mn 311.65 Mn - 2.52 Mn
6 Republic Digital Acquisition 310.50 Mn 309.63 Mn - 2.54 Mn
7 Siddhi Acquisition Corp (Cayman Islands) 288.97 Mn 288.97 Mn - 2.24 Mn
8 K&F Growth Acquisition 283.42 Mn 283.42 Mn - 2.67 Mn
9 Bold Eagle Acquisition 275.29 Mn 275.29 Mn - 2.17 Mn
10 Drugs Made In America Acquisition - - - 4.59 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 4.59 Mn
Sep 30, 2025 -46,158.00